Statistically, your risk for cancer goes up from the very first sip of alcohol. However, what’s lost in this messaging is how ...

Novo Nordisk’s Ozempic (semaglutide) has been approved by the US Food and Drug Administration (FDA) to reduce the risk of ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Wishbone Gold said it agreed to buy Evrensel Global Natural Resources, a private company owned by Chairman Anthony Moore, in a deal classified as a reverse takeover under London Stock Exchange rules.

Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market.

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight ...